SYNDAX PHARMACEUTICALS INC (SNDX) Institutional Shareholders

SYNDAX PHARMACEUTICALS INC (SNDX) is currently reported in institutional portfolios tracked by InsiderSet based on the latest available SEC Form 13F filings for the quarter ended June 30, 2026. The institutional investors covered on this page collectively reported approximately $2.31B in SNDX holdings during the latest filing period.

Blackrock, Inc. is currently the largest disclosed institutional shareholder of SNDX tracked by InsiderSet, reporting ownership valued at approximately $197.18M in its June 30, 2026 SEC Form 13F filing. Based on current market prices and the latest disclosed share count, the position is now estimated to be worth approximately $159.47M, representing an estimated loss of -19.12% since the filing period.

The top 10 institutional shareholders tracked on this page collectively account for approximately 46% of the total disclosed SNDX value among the investors covered in this analysis. Major shareholders include Blackrock, Inc., Kynam Capital Management, Lp, Goldman Sachs Group Inc, and several other long-term asset managers with concentrated positions in SYNDAX PHARMACEUTICALS INC (SNDX).

This page ranks the largest institutional SNDX shareholders using publicly disclosed SEC Form 13F data, including reported values, estimated current holding values, portfolio allocation percentages, ownership concentration metrics, and historical holding changes across major hedge funds and investment firms.

Institutional Holders

236

Total Reported Value

$2.31B

Largest Holder

Blackrock, Inc.

Largest Position

$197.18M

Insider Transactions (90d)

1

Latest Filing Quarter

Q2 2026

New Institutional Positions

53

Funds Exiting Positions

0

NameInvestor/ManagerPortfolio %QuantityReported BalanceCurrent Estimated ValueGain/loss Since FilingEstimated Portfolio Performance
Blackrock, Inc.0.00%9,020,006$197,177,353$159,473,706-$37,703,647-19.12%
Kynam Capital Management, Lp9.73%8,050,959$175,993,964$142,340,955-$33,653,009-19.12%
Goldman Sachs Group Inc0.01%5,861,265$128,127,253$103,627,165-$24,500,088-19.12%
State Street Corp0.00%5,658,424$123,693,149$100,040,936-$23,652,213-19.12%
Bank Of America Corp0.01%4,045,094$88,425,755$71,517,262-$16,908,493-19.12%
Vanguard Capital Management Llc0.00%3,927,892$85,863,719$69,445,131-$16,418,588-19.12%
Deerfield Management Company, L.P.0.86%3,779,900$82,628,614$66,828,632-$15,799,982-19.12%
Eversept Partners, Lp3.33%2,798,210$61,168,871$49,472,353-$11,696,518-19.12%
Geode Capital Management, Llc0.00%2,584,136$56,499,563$45,687,524-$10,812,039-19.14%
Hood River Capital Management Llc0.41%2,564,279$56,055,139$45,336,453-$10,718,686-19.12%
Kingdon Capital Management, L.L.C.7.37%2,500,000$54,650,000$44,200,000-$10,450,000-19.12%
Millennium Management Llc0.03%2,053,960$44,899,566$36,314,013-$8,585,553-19.12%
Vanguard Portfolio Management Llc0.00%1,921,796$42,010,461$33,977,353-$8,033,108-19.12%
Ubs Group Ag0.01%1,893,750$41,397,375$33,481,500-$7,915,875-19.12%
Elmind Capital, Lp10.19%1,855,000$40,550,300$32,796,400-$7,753,900-19.12%
Bnp Paribas Asset Management Holding S.A.0.04%1,790,173$39,133,182$31,650,259-$7,482,923-19.12%
Candriam S.C.A.0.17%1,696,040$37,039,763$29,985,987-$7,053,776-19.04%
Soleus Capital Management, L.P.1.23%1,628,039$35,588,933$28,783,730-$6,805,203-19.12%
Two Sigma Investments, Lp0.03%1,578,125$34,497,812$27,901,250-$6,596,562-19.12%
Orbimed Advisors Llc0.64%1,542,000$33,708,120$27,262,560-$6,445,560-19.12%
Nuveen, Llc0.01%1,364,575$29,829,610$24,125,686-$5,703,924-19.12%
Mpm Bioimpact Llc1.78%1,333,523$29,150,813$23,576,687-$5,574,126-19.12%
Aisling Capital Management Lp6.10%1,316,806$28,785,379$23,281,130-$5,504,249-19.12%
Woodline Partners Lp0.08%1,250,760$27,341,614$22,113,437-$5,228,177-19.12%
D. E. Shaw & Co., Inc.0.02%1,239,954$27,105,395$21,922,387-$5,183,008-19.12%
Silverarc Capital Management, Llc2.95%1,214,390$26,546,565$21,470,415-$5,076,150-19.12%
Prosight Management, Lp4.52%1,200,000$26,232,000$21,216,000-$5,016,000-19.12%
Catalio Capital Management, Lp4.44%1,196,807$25,144,915$21,159,548-$3,985,367-15.85%
Trails Edge Capital Partners, Lp3.85%1,110,000$24,264,600$19,624,800-$4,639,800-19.12%
Ensign Peak Advisors, Inc0.04%990,969$23,149,036$17,520,332-$5,628,704-24.32%
Algert Global Llc0.27%1,051,465$22,985,025$18,589,901-$4,395,124-19.12%
Bank Of New York Mellon Corp0.00%1,040,079$22,736,118$18,388,597-$4,347,521-19.12%
Sphera Funds Management Ltd.3.17%1,014,606$22,179,287$17,938,234-$4,241,053-19.12%
Loomis Sayles & Co L P0.03%923,624$20,190,420$16,329,672-$3,860,748-19.12%
Parkman Healthcare Partners Llc1.97%877,256$19,176,816$15,509,886-$3,666,930-19.12%
Palo Alto Investors Lp2.61%864,986$18,908,594$15,292,952-$3,615,642-19.12%
Aqr Capital Management Llc0.01%853,304$18,653,226$15,086,415-$3,566,811-19.12%
Northern Trust Corp0.00%845,537$18,483,439$14,949,094-$3,534,345-19.12%
Charles Schwab Investment Management Inc0.00%814,303$17,800,664$14,396,877-$3,403,787-19.12%
Vanguard Fiduciary Trust Co0.00%633,509$13,848,507$11,200,439-$2,648,068-19.12%
Morgan Stanley0.00%588,979$12,875,080$10,413,149-$2,461,931-19.12%
Rhenman & Partners Asset Management Ab1.16%560,250$12,247,065$9,905,220-$2,341,845-19.12%
Apis Capital Advisors, Llc1.18%556,000$12,154,160$9,830,080-$2,324,080-19.12%
Panagora Asset Management Inc0.04%546,517$11,946,862$9,662,421-$2,284,441-19.12%
Qube Research & Technologies Ltd0.01%477,182$10,431,199$8,436,578-$1,994,621-19.12%
First Trust Advisors Lp0.01%456,700$9,983,462$8,074,456-$1,909,006-19.12%
Susquehanna International Group, Llp0.01%454,101$9,926,648$8,028,506-$1,898,142-19.12%
Granahan Investment Management, Llc0.35%446,988$9,771,158$7,902,748-$1,868,410-19.12%
Knott David M Jr5.05%437,245$9,558,176$7,730,492-$1,827,684-19.12%
Jump Financial, Llc0.08%402,846$8,806,214$7,122,317-$1,683,897-19.12%
Showing 50 of 236

Frequently asked questions about SNDX

  • Who owns the most SNDX stock?

    The largest holders of SNDX are typically major institutional investors such as asset managers and hedge funds reporting on Form 13F. The table above ranks tracked superinvestors by reported position size using the latest available filings for SYNDAX PHARMACEUTICALS INC (SNDX).

  • Is SNDX widely held by superinvestors?

    Many widely followed stocks like SNDX appear across numerous superinvestor portfolios because of liquidity, index inclusion, and fundamentals. The holder count and table above show how broadly SNDX is represented among the institutional managers we track.

  • What do “Current Estimated Value”, “Gain/loss Since Filing”, and “Estimated Portfolio Performance” mean?

    Current Estimated Value is reported share quantity from the latest 13F times our most recent split-adjusted U.S. session close. Gain/loss Since Filing is that estimate minus the reported 13F dollar value; Estimated Portfolio Performance is that difference as a percent of the reported value. Green means the estimate is above the filing value; red means below (not purchase cost). If many filers share the same implied filing price per share, the performance % may match across rows. These are not official fund marks or live quotes.